Clark Estates Inc. NY Decreases Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Clark Estates Inc. NY decreased its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 7.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 208,250 shares of the biopharmaceutical company’s stock after selling 16,700 shares during the quarter. Catalyst Pharmaceuticals makes up 0.8% of Clark Estates Inc. NY’s investment portfolio, making the stock its 21st biggest holding. Clark Estates Inc. NY owned approximately 0.17% of Catalyst Pharmaceuticals worth $4,140,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of CPRX. Susquehanna Fundamental Investments LLC acquired a new position in shares of Catalyst Pharmaceuticals during the second quarter worth $258,000. Integral Health Asset Management LLC purchased a new stake in Catalyst Pharmaceuticals during the 2nd quarter worth about $4,260,000. GSA Capital Partners LLP purchased a new stake in Catalyst Pharmaceuticals during the 3rd quarter worth about $625,000. Vanguard Group Inc. boosted its position in shares of Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after acquiring an additional 860,244 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Catalyst Pharmaceuticals by 146.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company’s stock worth $7,285,000 after acquiring an additional 217,956 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $21.93 on Wednesday. Catalyst Pharmaceuticals, Inc. has a 1-year low of $13.00 and a 1-year high of $24.27. The stock has a market cap of $2.62 billion, a P/E ratio of 18.58, a P/E/G ratio of 3.26 and a beta of 0.75. The stock’s 50 day simple moving average is $21.14 and its 200 day simple moving average is $18.62.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Citigroup increased their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Stephens assumed coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an “overweight” rating and a $35.00 price objective on the stock. Finally, Truist Financial lifted their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $31.14.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.